AstraZeneca PLC
AZNDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 23, 2026 | $1.59 | 2026-02-20 | 2026-02-20 |
| September 8, 2025 | $0.52 | 2025-08-08 | 2025-08-08 |
| March 24, 2025 | $1.05 | 2025-02-21 | 2025-02-21 |
| September 9, 2024 | $0.50 | 2024-08-09 | 2024-08-09 |
| March 25, 2024 | $0.98 | 2024-02-22 | 2024-02-23 |
Dividends Summary
- Consistent Payer: AstraZeneca PLC has rewarded shareholders with 46 dividend payments over the past 23 years.
- Total Returned Value: Investors who held AZN shares during this period received a total of $41.12 per share in dividend income.
- Latest Payout: The most recent dividend of $1.59/share was paid 117 days ago, on March 23, 2026.
- Dividend Growth: Since 2003, the dividend payout has grown by 525.5%, from $0.26 to $1.59.
Company News
ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as...
ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions ...
The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% ...
The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities inc...
Pomerantz LLP announced investigations into potential securities fraud at AstraZeneca following the failure of its Phase-3 CARDIO-Transform trial for Wainua treatment, which caused the stock to drop 5.7%. The firm is also investigating claims against Alibaba Group and Franklin Covey Co.
